MCLEAN, Va., March 16, 2017 /PRNewswire/ -- Perthera, Inc., a McLean, VA-based precision medicine company, announced today that they have launched a blog, CancerTreatmentChoices.com, that focuses on the most current cancer research and science. In addition to other articles selected by the editors, the site includes new PubMed reports, a service provided by the US National Library of Medicine that currently contains 26 million citations of abstracts from healthcare and medical research journal articles.
Although Perthera also has a blog that features news about the company and other "soft" articles as part of its website, the new stand-alone site is entirely dedicated to scientific papers and news.
"We want CancerTreatmentChoices.com to become a go-to resource for patients, caregivers and medical and research professionals seeking access and updates about the most recent discoveries and opinions regarding cancer," said Perthera co-founder and Chief Science Officer, Emanuel "Chip" Petricoin, Ph.D. "In fact, we have bifurcated CancerTreatmentChoices.com with one level of articles for patients and their caregivers, and an even more academic level of articles for physicians. This is another of our efforts to democratize cancer care by helping cancer patients and their caregivers be empowered and well-informed when it comes to cancer treatment options," he continued.
Subha Madhavan, Ph.D., Perthera's Chief Bioinformatics Officer, stated that the inclusion of PubMed is a major attraction to the new site. "It is challenging even for medical experts to keep up with all the emerging literature, new treatments, and trials," she said. For example, she stated that 498 citations were returned for a recent search on PubMed for the terms Pancreatic + cancer + Erlotinib (Erlotinib is a drug that is effective in cancer patients with mutations in a gene called EGFR).
"We select and annotate key articles that highlight such associations between genes, diseases, and drugs so that a visitor to our blog site can readily search and retrieve the article they are looking for," she said, adding that Perthera's bioinformatics team prioritizes which articles to share on the blog site based on their relevancy.
Petricoin noted that the blog is an example of Perthera's expanding services in the field of precision medicine.
"We think precision medicine goes far beyond just providing genetic analysis or clinical trial matchmaking," said Petricoin. "We are continually adding new technology and services, and this blog is one example. We are also aggressively building our computational tools, responding to ideas and encouragement we are hearing from oncologists and other decision-makers in the healthcare system. We plan to evolve with the growth of precision medicine itself," he concluded.
ABOUT PERTHERA, INC.: Perthera is a founder- and growth fund-backed company founded in 2012 and based in McLean, VA, that has touched thousands of lives by providing precision medicine benefits to cancer patients, their loved ones, and the entire cancer care ecosystem. Perthera leverages biological, computational, and human information and expertise, through a growing family of integrated products and services often using the company's proprietary technology, systems, and data.
If you would like more information about this topic, please contact Doug Poretz at 703-408-1880 or email at [email protected].
SOURCE Perthera, Inc.